Nonsense and missense mutations in hemophilia A: estimate of the relative mutation rate at CG dinucleotides.

Hemophilia A is an X-linked disease of coagulation caused by deficiency of factor VIII. Using cloned cDNA and synthetic oligonucleotide probes, we have now screened 240 patients and found CG-to-TG transitions in an exon in nine. We have previously reported four of these patients; and here we report the remaining five, all of whom were severely affected. In one patient a TaqI site was lost in exon 23, and in the other four it was lost in exon 24. The novel exon 23 mutation is a CG-to-TG substitution at the codon for amino acid residue 2166, producing a nonsense codon in place of the normal codon for arginine. Similarly, the exon 24 mutations are also generated by CG-to-TG transitions, either on the sense strand producing nonsense mutations or on the antisense strand producing missense mutations (Arg to Gln) at position 2228. The novel missense mutations are the first such mutations observed in association with severe hemophilia A. These results provide further evidence that recurrent mutations are not uncommon in hemophilia A, and they also allow us to estimate that the extent of hypermutability of CG dinucleotides is 10-20 times greater than the average mutation rate for hemophilia A.

[1]  S. Antonarakis,et al.  Characterization of five partial deletions of the factor VIII gene. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[2]  C. Peschle,et al.  Hereditary thrombophilia: identification of nonsense and missense mutations in the protein C gene. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S. Antonarakis,et al.  Molecular genetics of hemophilia A in man (factor VIII deficiency). , 1987, Molecular biology & medicine.

[4]  S. Antonarakis,et al.  Recurrent mutations in haemophilia A give evidence for CpG mutation hotspots , 1986, Nature.

[5]  R. Kaufman,et al.  A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[6]  W. Wood,et al.  Identification of a missense mutation in the factor VIII gene of a mild hemophiliac. , 1986, Science.

[7]  R. Lawn,et al.  A new polymorphism in the factor VIII gene for prenatal diagnosis of hemophilia A. , 1986, Nucleic acids research.

[8]  D. Rees,et al.  Defective propeptide processing of blood clotting factor IX caused by mutation of arginine to glutamine at position −4 , 1986, Cell.

[9]  N. Duchange,et al.  Antithrombin III tours gene: identification of a point mutation leading to an arginine----cysteine replacement in a silent deficiency. , 1986, Nucleic acids research.

[10]  S. Antonarakis,et al.  Hemophilia A. Detection of molecular defects and of carriers by DNA analysis. , 1985, The New England journal of medicine.

[11]  D. Bonthron,et al.  Identification of a point mutation in the adenosine deaminase gene responsible for immunodeficiency. , 1985, The Journal of clinical investigation.

[12]  T. Kawakami,et al.  Posttranslational cleavage of proinsulin is blocked by a point mutation in familial hyperproinsulinemia. , 1985, The Journal of clinical investigation.

[13]  R. White,et al.  The telomeric region of the human X chromosome long arm: presence of a highly polymorphic DNA marker and analysis of recombination frequency. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[14]  B. Keyt,et al.  Structure of human factor VIII , 1984, Nature.

[15]  E. Chen,et al.  Characterization of the human factor VIII gene , 1984, Nature.

[16]  B. Keyt,et al.  Expression of active human factor VIII from recombinant DNA clones , 1984, Nature.

[17]  G. Knutson,et al.  Molecular cloning of a cDNA encoding human antihaemophilic factor , 1984, Nature.

[18]  M. Pembrey,et al.  A CLINICALLY USEFUL DNA PROBE CLOSELY LINKED TO HAEMOPHILIA A , 1984, The Lancet.

[19]  D. Barker,et al.  Restriction sites containing CpG show a higher frequency of polymorphism in human DNA , 1984, Cell.

[20]  K. Itakura,et al.  alpha 1-antitrypsin deficiency detection by direct analysis of the mutation in the gene. , 1983, Nature.

[21]  R Nussinov,et al.  Eukaryotic dinucleotide preference rules and their implications for degenerate codon usage. , 1981, Journal of molecular biology.

[22]  E. Kawashima,et al.  The use of synthetic oligonucleotides as hybridization probes. II. Hybridization of oligonucleotides of mixed sequence to rabbit beta-globin DNA. , 1981, Nucleic acids research.

[23]  A. Bird.  DNA methylation and the frequency of CpG in animal DNA. , 1980, Nucleic acids research.

[24]  P Chambon,et al.  DNA methylation: organ specific variations in the methylation pattern within and around ovalbumin and other chicken genes. , 1979, Nucleic acids research.

[25]  L. Hoyer,et al.  Immunoradiometric measurement of the factor VIII procoagulant antigen. , 1978, The Journal of clinical investigation.

[26]  Philip J. Farabaugh,et al.  Molecular basis of base substitution hotspots in Escherichia coli , 1978, Nature.

[27]  A. George.  The metabolic basis of inherited disease , 1961 .

[28]  K. Davies,et al.  Report of the committee on the genetic constitution of the X and Y chromosomes. , 1987, Cytogenetics and cell genetics.

[29]  J. Gitschier,et al.  Genetic mapping and diagnosis of haemophilia A achieved through a BclI polymorphism in the factor VIII gene , 1985, Nature.

[30]  E. Chen,et al.  Detection and sequence of mutations in the factor VIII gene of haemophiliacs          , 1985, Nature.

[31]  W. Salser.  Globin mRNA sequences: analysis of base pairing and evolutionary implications. , 1978, Cold Spring Harbor symposia on quantitative biology.

[32]  D. Green,et al.  A More Uniform Measurement of Factor VIII Inhibitors , 1975, Thrombosis and Haemostasis.

[33]  B. Lyons,et al.  Hemophilia A. , 1969, Oral surgery, oral medicine, and oral pathology.

[34]  R. Kaufman,et al.  A large region (=95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity , 2022 .